Prevalence of atheromatous and non-atheromatous cardiovascular disease by age in chronic kidney disease

Author:

Villain Cédric12,Metzger Marie2,Combe Christian34,Fouque Denis5,Frimat Luc67,Jacquelinet Christian28,Laville Maurice5,Briançon Serge7,Klein Julie910,Schanstra Joost P910,Robinson Bruce M11,Mansencal Nicolas212,Stengel Bénédicte2,Massy Ziad A12

Affiliation:

1. Service de Néphrologie-Dialyse, CHU Ambroise Paré, APHP, Boulogne-Billancourt, France

2. CESP, INSERM UMRS 1018, Université Paris-Sud, UVSQ, Université Paris-Saclay, Villejuif, France

3. Service de Néphrologie Transplantation Dialyse Aphérèses, CHU de Bordeaux, Bordeaux, France

4. INSERM Unité 1026, Université de Bordeaux, Bordeaux, France

5. Service de Néphrologie, Centre Hospitalier Lyon Sud, Université Lyon, UCBL, Carmen, Pierre-Bénite, France

6. CHRU Nancy-Brabois, Vandœuvre-lès-Nancy, France

7. INSERM CIC-EC CIE6 - EA 4360 Apemac, Nancy Université, Vandœuvre-lès-Nancy, France

8. Agence de Biomédecine, La Plaine Saint-Denis, France

9. INSERM Unité 1048, Institute of Cardiovascular and Metabolic Disease, Toulouse, France

10. Université Toulouse III Paul-Sabatier, Toulouse, France

11. Arbor Research Collaborative for Health, Ann Arbor, MI, USA

12. Service de Cardiologie, CHU Ambroise Paré, APHP, Boulogne-Billancourt, France

Abstract

Abstract Background Although chronic kidney disease (CKD) and age are major risk factors for cardiovascular disease (CVD), little is known about the relative proportions of atheromatous and non-atheromatous CVD by age in CKD patients. Methods We used baseline data from the French Chronic Kidney Disease-Renal Epidemiology and Information Network (CKD-REIN) cohort of 3033 patients (65% men) with CKD Stages 3–4 to study crude and adjusted associations between age, the estimated glomerular filtration rate (eGFR), atheromatous CVD (coronary artery disease, peripheral artery disease and stroke) and non-atheromatous CVD (heart failure, cardiac arrhythmia and valvular heart disease). Results Mean age was 66.8 and mean Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) eGFR was 32.9 mL/min/1.73 m2. In the <65, (65–74), (75–84) and ≥85 year age groups, the prevalence was, respectively, 18.7, 35.5, 42.9 and 37.8% for atheromatous CVD, and 14.9, 28.4, 38.1 and 56.4% for non-atheromatous CVD. After adjusting for albuminuria, sex and CVD risk factors, the odds ratio (OR) [95% confidence interval (CI)] for (65–74), (75–84) and ≥85 age groups (compared with the <65 group) was, respectively, 1.99 (1.61–2.46), 2.89 (2.30–3.62), 2.72 (1.77–4.18) for atheromatous CVD and 2.07 (1.66–2.58), 3.15 (2.50–3.97), 7.04 (4.67–10.61) for non-atheromatous CVD. Compared with patients with an eGFR ≥30 mL/min/1.73 m2, those with an eGFR <30 mL/min/1.73 m2 had a higher OR for atheromatous CVD [1.21 (1.01–1.44)] and non-atheromatous CVD [1.16 (0.97–1.38)]. Conclusions In this large cohort of CKD patients, both atheromatous and non-atheromatous CVD were highly prevalent and more frequent in older patients. In a given age group, the prevalence of atheromatous and non-atheromatous CVD was similar (except for a greater prevalence of non-atheromatous CVD after 85).

Funder

Agence Nationale de la Recherche

Programme Hospitalier de Recherche Clinique.

Amgen, Baxter, Fresenius Medical Care, GlaxoSmithKline

Merck Sharp & Dohme-Chibret

Otsuka Pharmaceutical

public–private partnership

eight pharmaceutical companies

MSD

Amgen

Baxter

Fresenius Medical Care

GlaxoSmithKline

Merck Sharp

Dohme-Chibret

Sanofi-Genzyme

Lilly

Otsuka

French government

Bayer

Publisher

Oxford University Press (OUP)

Subject

Transplantation,Nephrology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3